$anvs projections

Annovis Bio's financial projections appear to be challenging, with a negative EPS and a significant drop in stock price predicted by some analysts. Here's a detailed analysis:

1. Current Financial Performance: Annovis Bio's Basic EPS as of Q1 2024, is -$0.1. The net income for the same period is -$1.07 million, indicating a loss for the company. This financial performance suggests that the company is not profitable currently.

2. Analyst Price Targets: The average one-year price target for Annovis Bio is $34.17, with a high estimate of $75.60 and a low estimate of $13.13. This suggests that analysts have varying opinions on the stock's future performance. However, it's important to note that price targets are based on projections and can be influenced by many factors.
3. Stock Price Prediction: Some analysts predict a significant drop in the stock price, with one suggesting a potential decrease from $6.090 to $0.000001, which would be a -100.00% change. This is a stark prediction and should be taken with caution.
4. Analyst Ratings: Despite the negative financial performance, there are analysts who maintain a buy rating on the stock. For instance, HC Wainwright & Co. has reiterated a buy rating, indicating some confidence in the company's future prospects.

5. Long-Term Projections: The projected stock price by June 12, 2025, is $34.17, which is a significant increase from the current price. However, the projected EPS for the same period is -$0.86, which does not align with a positive outlook.
6. Market Sentiment: The sentiment around Annovis Bio appears to be cautious, with some analysts predicting a negative return on investment (ROI) based on their trades. For example, following Ram Selvaraju's trades for one month would result in a -7.33% average return.

In conclusion, while there are some positive signals from analysts like HC Wainwright & Co. maintaining a buy rating, the overall financial projections for Annovis Bio are not promising. The negative EPS, the significant drop in stock price predicted by some analysts, and the lack of revenue and earnings projections for 2025 suggest that the company's future is uncertain. Investors should approach Annovis Bio with caution, considering the high risk associated with such projections.